Search

everythinglearnresearchcommunity

for

Search:↓

Certain medications including flutamide, spironolactone, and others effectively reduce excessive hair growth in women, especially when combined with lifestyle changes.

Cyproterone acetate combined with ethinyl estradiol significantly reduced hirsutism in women.

Some medicines can reduce excessive hair growth in women, but more research is needed to compare treatments and consider side effects.

Obesity worsens Polycystic Ovary Syndrome symptoms, and weight loss is a key treatment.

Primary care for PCOS focuses on lifestyle changes, medication based on symptoms, and mental health, with diabetes screening and specialist referral for severe cases.

Early treatment and lifestyle changes are important for managing PCOS in young people to prevent long-term health issues.

PCOS is a common hormonal disorder in women, treated with lifestyle changes, medication, and patient education.

Most excessive hair growth is due to idiopathic hirsutism or PCOS; treatment starts with cosmetic methods and drugs like cyproterone acetate or spironolactone, with results in 6-12 months.

Losing weight, possibly through bariatric surgery, is key to improving PCOS and hyperandrogenism symptoms in obese patients.

Combining letrozole with metformin is the most effective treatment for inducing pregnancy in women with PCOS.

Hyperandrogenism, often causing excessive hair growth and acne, can be treated with methods like weight reduction, hair removal, various medications, and in the case of acne, topical treatments.

Aldactone effectively reduces hair thickness in women with excessive hair growth, both alone and with other treatments.

Spironolactone effectively makes hair shafts thinner in women with excessive hair growth.

Hormonal contraceptives are effective for teens but require careful consideration of side effects and individual health.

The document concludes that PCOS in adolescents is complex and requires comprehensive care to manage its symptoms and associated health risks.

Polycystic Ovary Syndrome (PCOS) is a common but often undiagnosed disorder in women that can cause irregular periods, infertility, and other symptoms, and can be managed with lifestyle changes, medication, and sometimes surgery.

The document concludes that more research is needed to include new treatments in guidelines for Polycystic Ovary Syndrome (PCOS).

The document concludes that effectively managing PCOS requires a multifaceted approach.

Oral contraceptives and antiandrogens are the best treatments for hirsutism.

Hirsutism treatment should focus more on patient needs and quality of life.

Polycystic ovarian disease symptoms can continue after menopause, making diagnosis and management in older women challenging.

The case emphasizes the need for careful screening in children for insulin resistance and related conditions.

Hormonal therapies, especially antiandrogens, can help manage Hidradenitis Suppurativa.

PCOS symptoms can be managed with medication and lifestyle changes.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

Hormonal treatments can improve acne, but they come with potential side effects and risks.

Antiandrogen therapies are beneficial for treating skin and hair conditions related to androgen levels.

Treatments for Polycystic Ovary Syndrome (PCOS) focus on reducing symptoms, restoring regular periods, and helping with pregnancy. Common treatments include hormone suppressors, fertility drugs, and insulin-sensitising agents.

Girls with PCOS have higher levels of certain androgens, which are linked to excess hair growth, but these androgens don't help diagnose PCOS.

The 2023 guideline for PCOS suggests using updated diagnostic criteria, assessing related health risks, and recommends lifestyle changes and specific treatments for symptoms and fertility issues.